-The Hindu Ranbaxy, one of India's largest pharmaceutical companies, has agreed to pay $500 million fines levied by U.S. authorities for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S. The deal struck on Monday, said to be the largest financial penalty against a generic drug company for violations of FDA standards, came...

-The Hindu The south leads in the number of medical and nursing seats, with for-profit private colleges dominating the scene. It will take major capacity expansion in the government sector to meet WHO norms on access to health professionals. India has achieved major organisational and technological successes but the health system's performance is abysmal. This cannot be attributed to poverty. It is poor health that places India 134th in the Human Development...

-Live Mint Move part of strategy to counter growing incidence of non-communicable diseases; course to be part of 2014 academic curriculum Concerned by the growing incidence of non-communicable diseases (NCD), the government wants to introduce a new, graded subject in school focusing on health education in classes IV to X. The course will be a part of 2014's academic curriculum and is being designed by the National Institute of Health and Family Welfare...

-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...